BIOSECURE Act - The potential $3.6bn+ gap, Impact on Jobs and Skills shifts with Amber Tong, Senior Editor at EndPoint News

BIOSECURE Act - The potential $3.6bn+ gap, Impact on Jobs and Skills shifts with Amber Tong, Senior Editor at EndPoint News

In this episode,Charles talks with Amber Tong, a senior editor at Endpoints News, about how the Biosecure Act could impact the biotech and pharma sectors.

Amber shares thoughts on how this law could change U.S.-China biopharma ties, jobs, and making medicines. We also look into how things are changing in this area, who might benefit or not, and the big global tensions that affect these shifts.

Here's what you are in for:

00:00 Introduction

00:33 Welcoming the Guest

02:36 Discussing the Biosecure Act

04:34 Impact on the Biotech Industry

07:17 Geopolitical Tensions and Historical Context

16:09 Potential Winners and Losers

35:16 Future Predictions and Conclusion

About Amber Tong

Amber Tong is a senior editor at Endpoints News, which is a global specialty publication covering the biotech and pharmaceutical industries. She's a reporter/editor with more than six years of experience covering the biopharma industry, with a particular focus on the growing role China plays on the global stage.


Amber is also at BIO San Diego 2024, go say hi.


Useful Information on BIOSECURE

Endpoints' latest articles:


BIO: China tensions, fixing gene therapy’s business model, and the stop-start market recovery

https://endpts.com/see-you-at-bio-china-tensions-fixing-gene-therapys-business-model-and-the-stop-start-market-recovery/

WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down

https://endpts.com/wuxi-became-a-critical-partner-to-biopharma-companies-theyre-not-ready-if-the-us-cracks-down/

The US could upend biopharma manufacturing. WuXi rivals have an opening

https://endpts.com/the-us-could-upend-biopharma-manufacturing-wuxi-rivals-have-an-opening/

US-China tensions threaten to ensnare additional Chinese biopharma contractors

https://endpts.com/us-china-tensions-threaten-to-ensnare-additional-chinese-biopharma-contractors/

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

https://endpts.com/new-biosecure-draft-features-2032-grandfather-clause-five-year-grace-period-for-added-companies/

BIO CEO defends the organization's about-face on the Biosecure Act

https://endpts.com/bio-ceo-defends-the-organizations-about-face-on-the-biosecure-act/

Medicxi backs Chinese biotech's next-gen KRAS G12C drug with $40M injection

https://endpts.com/medicxi-backs-d3-bios-next-gen-kras-g12c-drug-with-40m-injection/


About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.

He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(71)

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Jun 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Mai 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Mai 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Mai 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mar 42min

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

In this episode, I talked with Volker Wacheck, SVP & Head of Clinical Development at Taiho Oncology, where he shared how a PI role in Vienna led him into industry, and why the hardest part wasn’t leav...

9 Mar 29min

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

In this episode, I talked with Dr. Dena Grayson, a physician–scientist with over two decades in biotech drug development. At the time of this recording, she was SVP and Head of Clinical Development at...

24 Feb 31min

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space.Richard’s career began in ...

26 Jan 35min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-borsmorgen-okonominyhetene
rss-skravla-gar
livet-pa-veien-med-jan-erik-larssen
pengepodden-2
rss-pa-konto
finansredaksjonen
utbytte
tid-er-penger-en-podcast-med-peter-warren
okonomiamatorene
morgenkaffen-med-finansavisen
liberal-halvtime
lederpodden
rss-politisk-preik
rss-kron-podden
pengesnakk